Non-Stimulant ADHD Medication: What Adults Should Know in 2026
With the Adderall shortage still affecting patients nationwide, here's how Strattera, Qelbree, and other non-stimulant options compare — and who they're right for.
If you've spent the last few years calling pharmacy after pharmacy trying to fill an Adderall or Ritalin prescription, you're far from alone. A CDC survey published in late 2024 found that roughly 7 in 10 adults with ADHD who take a stimulant medication had trouble filling their prescription because of ongoing shortages — a crisis that started in October 2022 and, as of 2026, still hasn't fully resolved. For many patients, that disruption has made non-stimulant ADHD meds a serious option worth understanding, not just a fallback.
Why the Adderall Shortage Isn't Going Away Overnight
Stimulant ADHD medications — Adderall, Ritalin, Vyvanse, and their generics — are Schedule II controlled substances. That means the DEA sets a hard annual ceiling, called an Aggregate Production Quota, on how much of the active ingredient manufacturers are allowed to produce nationwide. When ADHD diagnoses and prescriptions climbed faster than those quotas did, a persistent supply gap opened up.
The DEA has raised quotas several times to try to close that gap — a roughly 25% increase to d-amphetamine production in October 2025, followed by 2026 quotas set about 14% above initial proposals after more than 5,000 public comments. Even with those increases, supply chain issues, manufacturing delays, and rising demand mean shortages of specific strengths and formulations are still being reported into 2026.
Non-stimulant medications aren't caught up in any of this. Atomoxetine, viloxazine, guanfacine, and clonidine are not controlled substances and aren't subject to DEA production quotas at all — supply has stayed stable throughout the entire stimulant shortage.
The Four FDA-Approved Non-Stimulant ADHD Meds
Only four non-stimulant medications currently carry FDA approval for ADHD, split into two mechanisms:
Norepinephrine reuptake inhibitors:
- Atomoxetine (Strattera) — the original non-stimulant, FDA-approved in 2003. Still the most commonly prescribed, and available as an inexpensive generic. Clinical trials show a meaningful effect on core ADHD symptoms, though it typically takes 2-6 weeks to reach full benefit.
- Viloxazine (Qelbree) — approved for children in 2021 and extended to adults in 2022. Works similarly to atomoxetine but may begin helping somewhat sooner — some pediatric trials showed a response within the first week. It's brand-only, so cost is usually higher than generic atomoxetine.
Alpha agonists:
- Guanfacine ER (Intuniv) — often used alone or combined with a stimulant, particularly helpful for impulsivity and emotional reactivity.
- Clonidine ER (Kapvay) — similar profile to guanfacine, sometimes preferred based on side-effect tolerance.
These four make up the FDA-approved non-stimulant ADHD medication category — there's no single "best" option, since the right choice depends on your symptoms, side-effect tolerance, and what else is going on with your health.
What About Wellbutrin? Understanding Off-Label Options
Bupropion (Wellbutrin) isn't one of the four FDA-approved non-stimulant medications listed above — it's an antidepressant that some providers, including ours, prescribe off-label for ADHD. "Off-label" means the medication wasn't originally studied and approved by the FDA specifically for ADHD, even though real clinical evidence and experience support its use in the right patients. It's not experimental or unusual — off-label prescribing is common and legal practice in psychiatry.
Bupropion affects dopamine and norepinephrine, which is part of why it can help with ADHD symptoms even without formal ADHD approval. It's often considered specifically for patients who:
- Have ADHD alongside depression, since bupropion can address both at once
- Haven't tolerated one of the four FDA-approved non-stimulants well
- Want to avoid both controlled substances and the specific side-effect profile of atomoxetine or viloxazine
As with any off-label medication, the decision should be made with a provider who can walk you through why it fits your specific situation.
Strattera vs. Adderall: What's the real difference?
Adderall and other stimulants generally produce a stronger, faster effect for most patients — often within hours. Strattera takes weeks to build up but avoids the controlled-substance status, the shortage risk, and the abuse potential that comes with a Schedule II medication. Neither is universally "better" — it depends on your symptom severity, medical history, and whether shortage risk or fast onset matters more to you.
Qelbree vs. Strattera: How do they compare?
Both work through a similar mechanism, and no head-to-head trial has shown one is clearly more effective than the other. The practical differences come down to cost (Strattera has a cheap generic; Qelbree is brand-only), and onset (Qelbree may start working slightly faster for some patients). The choice usually comes down to insurance coverage and how your body responds to each, not a clear efficacy edge.
Who Tends to Do Well on a Non-Stimulant
Non-stimulant ADHD meds aren't typically a provider's first choice when a patient has straightforward ADHD and no other complicating factors — stimulants generally work more strongly for most people. But they're often the right choice, not just a backup, for:
- Patients with a history of substance use — non-stimulants carry essentially no abuse potential, since they're not controlled substances
- Patients with anxiety alongside ADHD — stimulants can sometimes worsen anxiety symptoms; non-stimulants avoid that activation
- Patients with certain cardiac risk factors, where a stimulant's effect on heart rate and blood pressure is a bigger concern
- Patients who've been repeatedly unable to fill a stimulant prescription and need reliable, consistent access
- Patients who simply prefer to avoid a controlled substance, for personal or professional reasons
Do Non-Stimulant ADHD Meds Actually Work?
Yes, for most patients — though differently than stimulants. Non-stimulants build up gradually rather than acting immediately: most patients notice some improvement within 2-4 weeks, with full benefit sometimes taking 6-8 weeks. This is worth planning for — a non-stimulant isn't the right choice if you need symptom relief immediately, but it's often a better long-term fit once it's had time to work.
Common side effects differ by type: atomoxetine and viloxazine can cause nausea, appetite changes, and a modest increase in heart rate or blood pressure; guanfacine and clonidine tend to cause drowsiness and can lower blood pressure. None of the four require the kind of careful controlled-substance monitoring that stimulants do, though your provider will still want to check in during the first few weeks.
Common Questions About Non-Stimulant ADHD Medication
Are non-stimulant ADHD medications addictive?
No. None of the four FDA-approved non-stimulant ADHD meds — atomoxetine, viloxazine, guanfacine, or clonidine — are controlled substances, and none carry meaningful abuse or addiction potential. That's a key reason they're often preferred for patients with a history of substance use.
Can you take a stimulant and a non-stimulant ADHD medication together?
Yes, this is common. Guanfacine ER and clonidine ER in particular are frequently prescribed alongside a stimulant to address symptoms — like emotional reactivity or impulsivity — that the stimulant alone doesn't fully cover. Your provider can determine whether combination treatment makes sense for you.
Does non-stimulant ADHD medication suppress appetite?
It can, but usually less than stimulants. Atomoxetine and viloxazine may cause some appetite reduction, especially early on; guanfacine and clonidine typically don't affect appetite at all.
How HMB Approaches ADHD Treatment
Given how disruptive the stimulant shortage has been — and how cautious the DEA has become around Schedule II prescribing generally — our psychiatric providers take a deliberately careful approach to ADHD diagnosis and treatment. We don't diagnose ADHD on a first visit. Instead, our process includes a full evaluation, collateral information from people who know you well, and follow-up cognitive testing to confirm what's actually going on before any medication — stimulant or non-stimulant — is prescribed.
One clarification that matters here: this isn't the same as the long, expensive, hours-long comprehensive neuropsychological testing some patients expect (often needed for school or workplace accommodation requests). We don't offer that specific type of testing — our evaluation process is focused on accurate diagnosis and safe, appropriate treatment, not accommodation documentation.
If you've been struggling with the stimulant shortage, dealing with side effects, or simply want to understand whether a non-stimulant medication makes sense for you, our team can walk you through the options as part of a full evaluation.
Recent Posts
